SRX246 is a potent, CNS-penetrant, highly selective, orally bioavailable Vasotocin 1a (V1a) receptor antagonist ( K i =0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 can be used for treatment of stress-related disorders In Vivo SRX246 (2 mg/kg; i.v.) treatment shows that the C max , AUC 0-∞ and t 1/2 values are 953 ng/mL, 1141 ng ▪h/mL, and 6.02 hours, respectively, in plasma pharmacokinetics. Following an oral administration (dose 20 mg/kg), The C max , AUC 0-∞ and t 1/2 values are 98.4 ng/mL, 624 ng ▪h/mL and 2.38 hours, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats Dosage: 2 mg/kg (20 mg/kg for p.o.) Administration: i.v. (Pharmacokinetic Analysis) Result: Following i.v. administration, the plasma concentration declined steadily with a half-life (t 1/2 ) of 6 hours. The C max and AUC 0-∞ values are 953 ng/mL, 1141 ng ▪h/mL, 6.02 hours. Following an oral administration, the C max , AUC 0-∞ and t 1/2 values 98.4 ng/mL, 624 ng ▪h/mL and 2.38 hours, respectively. Form:Solid IC50& Target:Ki: 0.3 nM (human Vasotocin 1a receptor)